7
Participants
Start Date
December 19, 2018
Primary Completion Date
April 20, 2023
Study Completion Date
September 18, 2023
IMA201 Product
The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
IMADetect®
IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials with investigational IMA201 therapy. IMADetect® is intended for investigational use only.
University of Pittsburgh Medical Center, Pittsburgh
Universitätsklinikum Hamburg-Eppendorf, Hamburg
Universitätsklinikum Bonn, Venusberg-Campus 1, Bonn
University of Texas MD Anderson Cancer Center, Houston
Universitätsklinikum Carl Gustav Carus, Fetscherstr. 74, Dresden
Immatics US, Inc.
INDUSTRY